Moderate hypofractionation in intermediate and high risk, localized prostate cancer: Health-related quality of life from the randomized, phase 3 HYPRO trial.
International Journal of Radiation Oncology*Biology*Physics（2019）
Abstract
Non-inferiority of the hypofractionated treatment was not demonstrated for genitourinary and gastrointestinal quality of life, and therefore we cannot rule out that relevant differences may exist between both treatments. Non-inferiority of hypofractionation was demonstrated for androgen-deprivation therapy-related symptoms, sexual activity and sexual function.
MoreTranslated text
Key words
Patient-reported outcome measures,hypofractionated radiation oncology,intermediate- and high-risk prostate cancer,quality of life,randomized clinical trial
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined